MDS Nordion (MDZ) Announces Publication of First European Study with Y-90 on the Use of TheraSphere
MDS Nordion, of MDS, Inc. (NYSE: MDZ), announces the first large European study using Yttrium-90 (Y-90) glass microspheres has been published on the use of TheraSphere.
TheraSphere is an radioembolisation therapy for the localised treatment of patients with advanced hepatocellular carcinoma (HCC) or primary liver cancer.
Conducted at MDS Nordion’s European Centre of Excellence in Essen, Germany, the study involved 108 patients, none of whom were eligible for conventional locoregional therapies. Patients achieved a median overall survival of 16.4 months with minimal damage to the surrounding healthy tissue, even in patients with advanced liver cirrhosis or portal vein thrombosis. No lung or visceral toxicity was observed. The most frequently observed adverse event was a transient fatigue-syndrome.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
TheraSphere is an radioembolisation therapy for the localised treatment of patients with advanced hepatocellular carcinoma (HCC) or primary liver cancer.
Conducted at MDS Nordion’s European Centre of Excellence in Essen, Germany, the study involved 108 patients, none of whom were eligible for conventional locoregional therapies. Patients achieved a median overall survival of 16.4 months with minimal damage to the surrounding healthy tissue, even in patients with advanced liver cirrhosis or portal vein thrombosis. No lung or visceral toxicity was observed. The most frequently observed adverse event was a transient fatigue-syndrome.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
- Medivation (MDVN) Submits NDA for Enzalutamide to U.S. FDA
- Cytokinetics (CYTK) Opens Second Cohort for ATOMIC-AHF Phase IIb
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
